Skip to main content
Clinical Trials/JPRN-UMIN000025278
JPRN-UMIN000025278
Completed
未知

An observational study of EGFR mutation status by circulating tumor DNA during the osimertinib treatment of lung cancer harboring EGFR activating and T790M mutations. - An observational study of plasma EGFR mutation status during osimertinib treatment.

Miyagi Cancer Center0 sites60 target enrollmentDecember 20, 2016
Conditionslung Cancer

Overview

Phase
未知
Intervention
Not specified
Conditions
lung Cancer
Sponsor
Miyagi Cancer Center
Enrollment
60
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 20, 2016
End Date
March 31, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Having an evidence of ILD or pulmonary fibrosis complication on chest X\-ray. 2\. Having a history or serious complications as bellows: 1\) uncontrollable angina pectoris, cardial infarction within 3 months before enrollment, or heart failure. 2\) uncontrollable diabetes or hypertension. 3\) Severe infectious disease.. 4\) gastrointestinal dysfunction with severe diarrhea. 3\. Impossible to take drugs orally. 4\. Inadequate case considered from drug package insert of osimertinib.

Outcomes

Primary Outcomes

Not specified

Similar Trials